famotidine has been researched along with Heartburn in 22 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Heartburn: Substernal pain or burning sensation, usually associated with regurgitation of gastric juice into the esophagus.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy and safety of hydrotalcite with the H2 receptor antagonist famotidine and placebo in the on-demand treatment of acute heartburn under daily practice conditions." | 9.12 | On-demand treatment of acute heartburn with the antacid hydrotalcite compared with famotidine and placebo: randomized double-blind cross-over study. ( Caspary, WF; Holtmann, G; Holtmeier, W; Weingärtner, U, 2007) |
| "To investigate the efficacy of famotidine and omeprazole in the treatment of gastro-oesophageal reflux disease, especially non-erosive gastro-oesophageal reflux disease." | 9.11 | Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease. ( Fujita, F; Itoh, K; Itoh, M; Joh, T; Kataoka, H; Kubota, E; Mori, Y; Nakao, H; Ogasawara, N; Ohara, H; Oshima, T; Sasaki, M; Sobue, S; Tanida, S; Togawa, S; Wada, T; Yamada, T, 2005) |
| "180 patients suffering from frequent heartburn and endoscopically normal oesophageal mucosa or mild non-erosive oesophagitis entered an open, multicentre study to evaluate the 6-week safety profile and efficacy on symptom relief of famotidine (CAS 76824-35-6, Pepdul mite), a potent and long-acting H2-receptor antagonist." | 9.08 | [Symptomatic therapy with famotidine in non-erosive gastro-esophageal reflux. Results of an open multicenter study]. ( Heckers, H; Lübbecke, F, 1995) |
| "To determine whether, in a susceptible population, dosing with 10 mg famotidine 1 h before an evening meal could decrease the interference with sleep caused by heartburn." | 9.08 | Low dose famotidine in the prevention of sleep disturbance caused by heartburn after an evening meal. ( Cottrell, J; Mann, SG; McCarroll, K; Mehentee, J; Morton, R; Murakami, A; Rao, AN, 1995) |
| "To establish whether patients taking famotidine 10 mg to treat an episode of heartburn were protected from a recurrence of symptoms after a subsequent test meal." | 9.08 | Prevention of heartburn relapse by low-dose famotidine: a test meal model for duration of symptom control. ( Cottrell, J; Mann, SG; Murakami, A; Rao, AN; Stauffer, L, 1997) |
| "We conducted a double-blind, placebo-controlled, multicenter trial comparing the efficacy of famotidine 40 mg administered at bedtime (HS), 20 mg given twice daily (BID), and placebo to relieve heartburn and to heal endoscopically documented esophageal erosions or ulcerations." | 9.07 | Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group. ( Berlin, RG; Bradstreet, DC; Humphries, TJ; Sabesin, SM; Walton-Bowen, KL; Zaidi, S, 1991) |
| "In 8,460 patients who completed the protocol, famotidine administration significantly attenuated epigastralgia, epigastric fullness, and heartburn, and famotidine also attenuated abdominal symptom-related QOL impairment in all patients with chronic symptomatic gastritis, in those with FD-like symptoms without organic disease, and in those with FD as defined by the Rome III criteria." | 7.78 | Therapeutic effects of famotidine on chronic symptomatic gastritis: subgroup analysis from FUTURE study. ( Chiba, T; Kinoshita, Y, 2012) |
| "All had classic symptoms of gastro-oesophageal reflux but normal results of upper gastrointestinal endoscopy and oesophageal mucosal histological tests." | 6.67 | Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease. ( de Caestecker, JS; Marrero, JM; Maxwell, JD, 1994) |
| " Most studies have documented the need for multiple daily dosing with H2-antagonists to achieve clinical and statistical efficacy for symptom relief." | 6.67 | Famotidine (20 mg) b.d. relieves gastrooesophageal reflux symptoms in patients without erosive oesophagitis. Famotidine/GERD Investigation Group. ( Barden, P; Decktor, DL; Holt, S; Hufnagel, K; Humphries, TJ; Moyer, R; Pevelery, M; Robinsen, M; Root, J; Stone, RC, 1991) |
| "Lafutidine has a high endoscopic healing rate and improves symptoms of heartburn in patients with mild reflux esophagitis." | 5.14 | A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis. ( Haruma, K; Kinoshita, Y; Kusano, M; Ohara, S, 2010) |
| " The percentage of days without heartburn, the primary end point of the efficacy evaluation, was 62% for 40 mg and 59% for 20 mg of famotidine, and 55% for placebo, with a statistically significant difference between the 40-mg dose and placebo (P = 0." | 5.13 | A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease. ( Haruma, K; Hongo, M; Kinoshita, Y, 2008) |
| "To compare the efficacy and safety of hydrotalcite with the H2 receptor antagonist famotidine and placebo in the on-demand treatment of acute heartburn under daily practice conditions." | 5.12 | On-demand treatment of acute heartburn with the antacid hydrotalcite compared with famotidine and placebo: randomized double-blind cross-over study. ( Caspary, WF; Holtmann, G; Holtmeier, W; Weingärtner, U, 2007) |
| "To investigate the efficacy of famotidine and omeprazole in the treatment of gastro-oesophageal reflux disease, especially non-erosive gastro-oesophageal reflux disease." | 5.11 | Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease. ( Fujita, F; Itoh, K; Itoh, M; Joh, T; Kataoka, H; Kubota, E; Mori, Y; Nakao, H; Ogasawara, N; Ohara, H; Oshima, T; Sasaki, M; Sobue, S; Tanida, S; Togawa, S; Wada, T; Yamada, T, 2005) |
| "Heartburn, regurgitation and dysphagia were hardly found in any group at 8 weeks after 15 mg or 30 mg lansoprazole treatment." | 5.11 | Management of symptoms in step-down therapy of gastroesophageal reflux disease. ( Iida, T; Kishikawa, H; Mine, S; Tabata, T; Tanaka, Y, 2005) |
| "180 patients suffering from frequent heartburn and endoscopically normal oesophageal mucosa or mild non-erosive oesophagitis entered an open, multicentre study to evaluate the 6-week safety profile and efficacy on symptom relief of famotidine (CAS 76824-35-6, Pepdul mite), a potent and long-acting H2-receptor antagonist." | 5.08 | [Symptomatic therapy with famotidine in non-erosive gastro-esophageal reflux. Results of an open multicenter study]. ( Heckers, H; Lübbecke, F, 1995) |
| "To determine whether, in a susceptible population, dosing with 10 mg famotidine 1 h before an evening meal could decrease the interference with sleep caused by heartburn." | 5.08 | Low dose famotidine in the prevention of sleep disturbance caused by heartburn after an evening meal. ( Cottrell, J; Mann, SG; McCarroll, K; Mehentee, J; Morton, R; Murakami, A; Rao, AN, 1995) |
| "To establish whether patients taking famotidine 10 mg to treat an episode of heartburn were protected from a recurrence of symptoms after a subsequent test meal." | 5.08 | Prevention of heartburn relapse by low-dose famotidine: a test meal model for duration of symptom control. ( Cottrell, J; Mann, SG; Murakami, A; Rao, AN; Stauffer, L, 1997) |
| "We conducted a double-blind, placebo-controlled, multicenter trial comparing the efficacy of famotidine 40 mg administered at bedtime (HS), 20 mg given twice daily (BID), and placebo to relieve heartburn and to heal endoscopically documented esophageal erosions or ulcerations." | 5.07 | Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group. ( Berlin, RG; Bradstreet, DC; Humphries, TJ; Sabesin, SM; Walton-Bowen, KL; Zaidi, S, 1991) |
| "In 8,460 patients who completed the protocol, famotidine administration significantly attenuated epigastralgia, epigastric fullness, and heartburn, and famotidine also attenuated abdominal symptom-related QOL impairment in all patients with chronic symptomatic gastritis, in those with FD-like symptoms without organic disease, and in those with FD as defined by the Rome III criteria." | 3.78 | Therapeutic effects of famotidine on chronic symptomatic gastritis: subgroup analysis from FUTURE study. ( Chiba, T; Kinoshita, Y, 2012) |
| "The aim of this study was to compare the direct medical costs associated with the treatment of patients with heartburn/nonulcer dyspepsia under 2 scenarios: (i) no nonprescription histamine H2 receptor antagonist (H2RA) is available (the 'status quo scenario'); and (ii) the H2RA famotidine (at a daily dosage of 10mg) is available over-the-counter (OTC) at retail pharmacies (the 'OTC scenario')." | 3.69 | Switching the histamine H2 receptor antagonist famotidine to nonprescription status in Canada. An economic evaluation. ( Goeree, R; Henke, CJ; O'Brien, BJ; Tasch, RF, 1996) |
| "Healthy subjects (12 male, 12 female) were dosed on three occasions with single oral doses of placebo, ranitidine, 75 mg, and famotidine, 10 mg, 1 h after lunch." | 2.70 | Control of intragastric acidity with over-the-counter doses of ranitidine or famotidine. ( Hamilton, MI; Pounder, RE; Sercombe, J, 2001) |
| " The time to onset of action and the degree of gastric acid inhibition of the H2 -RAs famotidine and cimetidine at dosage levels approved for over-the-counter use (10 mg famotidine and 200 mg cimetidine) were compared." | 2.69 | The action of 10 mg famotidine versus 200 mg cimetidine: onset and magnitude of antisecretory action within the first 2 hours after administration. ( Decktor, D; Houle, JM; Pierce, CH, 1998) |
| "All had classic symptoms of gastro-oesophageal reflux but normal results of upper gastrointestinal endoscopy and oesophageal mucosal histological tests." | 2.67 | Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease. ( de Caestecker, JS; Marrero, JM; Maxwell, JD, 1994) |
| " Most studies have documented the need for multiple daily dosing with H2-antagonists to achieve clinical and statistical efficacy for symptom relief." | 2.67 | Famotidine (20 mg) b.d. relieves gastrooesophageal reflux symptoms in patients without erosive oesophagitis. Famotidine/GERD Investigation Group. ( Barden, P; Decktor, DL; Holt, S; Hufnagel, K; Humphries, TJ; Moyer, R; Pevelery, M; Robinsen, M; Root, J; Stone, RC, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (54.55) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 3 (13.64) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Malone, RW | 1 |
| Kormos, W | 1 |
| Hongo, M | 1 |
| Kinoshita, Y | 3 |
| Haruma, K | 2 |
| Ohara, S | 1 |
| Kusano, M | 1 |
| Chiba, T | 1 |
| Wada, T | 1 |
| Sasaki, M | 1 |
| Kataoka, H | 1 |
| Tanida, S | 1 |
| Itoh, K | 1 |
| Ogasawara, N | 1 |
| Oshima, T | 1 |
| Togawa, S | 1 |
| Kubota, E | 1 |
| Yamada, T | 1 |
| Mori, Y | 1 |
| Fujita, F | 1 |
| Ohara, H | 1 |
| Nakao, H | 1 |
| Sobue, S | 1 |
| Joh, T | 1 |
| Itoh, M | 1 |
| Gould, AL | 1 |
| Mine, S | 1 |
| Iida, T | 1 |
| Tabata, T | 1 |
| Kishikawa, H | 1 |
| Tanaka, Y | 1 |
| Holtmeier, W | 1 |
| Holtmann, G | 1 |
| Caspary, WF | 1 |
| Weingärtner, U | 1 |
| Umeda, N | 1 |
| Miki, K | 1 |
| Hoshino, E | 1 |
| Heckers, H | 1 |
| Lübbecke, F | 1 |
| Marrero, JM | 1 |
| de Caestecker, JS | 1 |
| Maxwell, JD | 1 |
| Mann, SG | 2 |
| Murakami, A | 2 |
| McCarroll, K | 1 |
| Rao, AN | 2 |
| Cottrell, J | 2 |
| Mehentee, J | 1 |
| Morton, R | 1 |
| Ahmed, W | 1 |
| Qureshi, H | 1 |
| Alam, SE | 1 |
| Zuberi, SJ | 1 |
| Decktor, DL | 2 |
| Ciccone, PE | 1 |
| Stauffer, L | 1 |
| Decktor, D | 1 |
| Houle, JM | 1 |
| Pierce, CH | 1 |
| Tasch, RF | 1 |
| Goeree, R | 1 |
| Henke, CJ | 1 |
| O'Brien, BJ | 1 |
| Wilhelmsen, I | 1 |
| Hatlebakk, JG | 1 |
| Olafsson, S | 1 |
| Berstad, A | 1 |
| Hamilton, MI | 1 |
| Sercombe, J | 1 |
| Pounder, RE | 1 |
| Sabesin, SM | 1 |
| Berlin, RG | 1 |
| Humphries, TJ | 2 |
| Bradstreet, DC | 1 |
| Walton-Bowen, KL | 1 |
| Zaidi, S | 1 |
| Robinsen, M | 1 |
| Stone, RC | 1 |
| Pevelery, M | 1 |
| Barden, P | 1 |
| Moyer, R | 1 |
| Holt, S | 1 |
| Root, J | 1 |
| Hufnagel, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| YM1170 Phase 2/3 Study: A Double Blind, Placebo Controlled, Group-comparison Study in Patients With Non-erosive Gastroesophageal Reflux Disease[NCT00141960] | Phase 2/Phase 3 | 480 participants | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 trials available for famotidine and Heartburn
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease.
Topics: Double-Blind Method; Famotidine; Female; Gastroesophageal Reflux; Heartburn; Histamine H2 Antagonist | 2008 |
A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis.
Topics: Acetamides; Double-Blind Method; Esophagitis, Peptic; Esophagoscopy; Famotidine; Female; Heartburn; | 2010 |
Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
Topics: Analysis of Variance; Anti-Ulcer Agents; Drug Therapy, Combination; Famotidine; Female; Gastroesopha | 2005 |
Management of symptoms in step-down therapy of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Deglutition Disorders; Endosonography; Enzyme Inhibit | 2005 |
On-demand treatment of acute heartburn with the antacid hydrotalcite compared with famotidine and placebo: randomized double-blind cross-over study.
Topics: Acute Disease; Adolescent; Adult; Aged; Aluminum Hydroxide; Antacids; Cross-Over Studies; Double-Bli | 2007 |
Lansoprazole versus famotidine in symptomatic reflux esophagitis: a randomized, multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Cross-Over Studies | 1995 |
[Symptomatic therapy with famotidine in non-erosive gastro-esophageal reflux. Results of an open multicenter study].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Endoscopy, Gastrointestinal; Famotidine; Femal | 1995 |
Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease.
Topics: Adult; Aged; Double-Blind Method; Esophagus; Famotidine; Female; Gastroesophageal Reflux; Heartburn; | 1994 |
Low dose famotidine in the prevention of sleep disturbance caused by heartburn after an evening meal.
Topics: Adult; Aged; Diet; Famotidine; Female; Follow-Up Studies; Heartburn; Humans; Male; Middle Aged; Slee | 1995 |
Prevention of heartburn relapse by low-dose famotidine: a test meal model for duration of symptom control.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alginates; Double-Blind Method; Famotidine; Female; Gluc | 1997 |
The action of 10 mg famotidine versus 200 mg cimetidine: onset and magnitude of antisecretory action within the first 2 hours after administration.
Topics: Administration, Oral; Adult; Anti-Ulcer Agents; Cimetidine; Cross-Over Studies; Drug Monitoring; Fam | 1998 |
On demand therapy of reflux oesophagitis--a prospective study of symptoms, patient satisfaction and quality of life.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Esophagitis, Peptic; Famotidine; Female; Gastric | 1999 |
Control of intragastric acidity with over-the-counter doses of ranitidine or famotidine.
Topics: Adult; Cross-Over Studies; Famotidine; Female; Gastric Acid; Gastric Acidity Determination; Heartbur | 2001 |
Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Esophago | 1991 |
Famotidine (20 mg) b.d. relieves gastrooesophageal reflux symptoms in patients without erosive oesophagitis. Famotidine/GERD Investigation Group.
Topics: Administration, Oral; Adult; Antacids; Double-Blind Method; Drug Administration Schedule; Esophagiti | 1991 |
7 other studies available for famotidine and Heartburn
| Article | Year |
|---|---|
More Than Just Heartburn: Does Famotidine Effectively Treat Patients with COVID-19?
Topics: COVID-19; Famotidine; Gastroesophageal Reflux; Heartburn; Humans; SARS-CoV-2 | 2021 |
On call. I have heartburn a few times a month. My doctor suggested I use a generic H₂blocker like famotidine or ranitidine. Is this better than an antacid?
Topics: Acute Disease; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drugs, Generic; Famotidine; Hear | 2014 |
Therapeutic effects of famotidine on chronic symptomatic gastritis: subgroup analysis from FUTURE study.
Topics: Adult; Aged; Chronic Disease; Dyspepsia; Famotidine; Female; Gastritis; Heartburn; Histamine H2 Anta | 2012 |
Bayesian analysis of multicentre trial outcomes.
Topics: Antacids; Bayes Theorem; Double-Blind Method; Drugs, Investigational; Famotidine; Finasteride; Heart | 2005 |
Famotidine 40mg B.I.D. in the treatment of reflux oesophagitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Esophagitis, Peptic; Esoph | 1995 |
Effects of famotidine vs antacid on gastric acidity: onset of action and symptom relief.
Topics: Antacids; Anti-Ulcer Agents; Calcium Carbonate; Famotidine; Gastric Acid; Heartburn; Humans | 1996 |
Switching the histamine H2 receptor antagonist famotidine to nonprescription status in Canada. An economic evaluation.
Topics: Canada; Decision Support Techniques; Famotidine; Heartburn; Histamine H2 Antagonists; Humans; Nonpre | 1996 |